×
About 22,568 results

ALLMedicine™ Bladder Cancer Center

Research & Reviews  7,783 results

Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testi...
https://doi.org/10.1001/jamanetworkopen.2022.13070
JAMA Network Open; Yap TA, Ashok A et. al.

May 21st, 2022 - Germline testing guidelines are suggested for specific disease types or a family history of cancer, yet alterations are found in cancer types in which germline testing is not routinely indicated. The clinical role of identifying germline variants ...

A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder
https://clinicaltrials.gov/ct2/show/NCT04919512

May 20th, 2022 - Bladder cancer is the tenth most common malignancy worldwide. Approximately 25 percent (%) of all new bladder cancer participants present with muscle invasive bladder cancer (MIBC) at the time of diagnosis, and roughly 50% will ultimately develop ...

Oncologic outcomes of Bacillus Calmette-Guérin therapy in elderly patients with non-mus...
https://doi.org/10.1371/journal.pone.0267934
PloS One; Aghamir SMK, Khatami F et. al.

May 20th, 2022 - There is a challenge on the medical efficacy of intravesical Bacillus Calmette-Guérin (BCG) therapy and the power of the immune system boosting, which can be influenced by the age of the non-muscle-invasive bladder cancer (NMIBC) patients. This me...

Clinical Performance Evaluation of the C2i-Test
https://clinicaltrials.gov/ct2/show/NCT05221827

May 20th, 2022 - The C2i-WGS-MRD Test (hereinafter referred to as C2i-Test), a personalized molecular circulating tumor DNA (ctDNA) test, is an in vitro qualitative test that uses next generation sequencing (NGS) based whole-genome sequencing (WGS) data for detect...

see more →

Guidelines  29 results

Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
https://doi.org/10.1016/j.annonc.2021.11.012
Annals of Oncology : Official Journal of the European Soc... Powles T, Bellmunt J et. al.

Dec 4th, 2021 - Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.|2021|Powles T,Bellmunt J,Comperat E,De Santis M,Huddart R,|drug therapy,therapeutic use,drug therapy,therapy,

The Genitourinary Pathology Society Update on Classification and Grading of Flat and Pa...
https://doi.org/10.1097/PAP.0000000000000308
Advances in Anatomic Pathology; Amin MB, Comperat E et. al.

Jun 16th, 2021 - The Genitourinary Pathology Society (GUPS) undertook a critical review of the recent advances in bladder neoplasia with a focus on issues relevant to the practicing surgical pathologist for the understanding and effective reporting of bladder canc...

The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1...
https://doi.org/10.1097/PAP.0000000000000309
Advances in Anatomic Pathology; Compérat E, Amin MB et. al.

Jun 16th, 2021 - The Genitourinary Pathology Society (GUPS) undertook a critical review of the recent advances in bladder cancer focusing on important topics of high interest for the practicing surgical pathologist and urologist. This review represents the second ...

ACR Appropriateness Criteria® Post-Treatment Surveillance of Bladder Cancer: 2021 Update.
https://doi.org/10.1016/j.jacr.2021.02.011
Journal of the American College of Radiology : JACR; , Allen BC et. al.

May 8th, 2021 - Urothelial cancer is the second most common cancer, and cause of cancer death, related to the genitourinary tract. The goals of surveillance imaging after the treatment of urothelial cancer of the urinary bladder are to detect new or previously un...

European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Ca...
https://doi.org/10.1016/j.eururo.2020.03.055
European Urology; Witjes JA, Bruins HM et. al.

May 4th, 2020 - This overview presents the updated European Association of Urology (EAU) guidelines for muscle-invasive and metastatic bladder cancer (MMIBC). To provide practical evidence-based recommendations and consensus statements on the clinical management ...

see more →

Drugs  19 results see all →

Clinicaltrials.gov  302 results

A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder
https://clinicaltrials.gov/ct2/show/NCT04919512

May 20th, 2022 - Bladder cancer is the tenth most common malignancy worldwide. Approximately 25 percent (%) of all new bladder cancer participants present with muscle invasive bladder cancer (MIBC) at the time of diagnosis, and roughly 50% will ultimately develop ...

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
https://clinicaltrials.gov/ct2/show/NCT05316155

May 20th, 2022 - Bladder cancer is the most common malignancy worldwide where non-muscle invasive (NMIBC), requiring intensive regimens of frequent monitoring, local resection (transurethral resection of bladder [TURBT]). This study enrolls participants with non-m...

Clinical Performance Evaluation of the C2i-Test
https://clinicaltrials.gov/ct2/show/NCT05221827

May 20th, 2022 - The C2i-WGS-MRD Test (hereinafter referred to as C2i-Test), a personalized molecular circulating tumor DNA (ctDNA) test, is an in vitro qualitative test that uses next generation sequencing (NGS) based whole-genome sequencing (WGS) data for detect...

Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer
https://clinicaltrials.gov/ct2/show/NCT03528694

May 19th, 2022 - Patients will be randomized in a 1:1:1 ratio to receive treatment with Durvalumab + BCG combination therapies, or Standard of Care (SoC) therapy.

A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who...
https://clinicaltrials.gov/ct2/show/NCT04209114

May 18th, 2022 - The purpose of the study is to see if treatment with nivolumab plus bempegaldesleukin or nivolumab alone, before and after surgery to remove the bladder, is more effective than surgery alone in participants with high-risk urothelial cancer, includ...

see more →

News  874 results

Stop Calling It Cancer; AI Gets a Win in Bladder Cancer; Lack of Price Transparency
https://www.medpagetoday.com/hematologyoncology/prostatecancer/98370

Apr 22nd, 2022 - A group of prostate cancer specialists, joined by MedPage Today contributor and prostate cancer patient Howard Wolinsky, made a case to stop referring to low-grade prostate cancer (Gleason ≤6) as cancer. (Journal of Clinical Oncology) The Internat...

Cancer Group Urges Oncologists to Fight Medical Misinformation
https://www.medpagetoday.com/hematologyoncology/othercancers/98033

Apr 4th, 2022 - Healthcare professionals need to be engaged in research to better understand cancer misinformation, how to combat it, and how to reach the population most affected by online health misinformation, according to a Collaboration for Outcomes Using So...

Neoadjuvant Atezolizumab/Chemo Shows Encouraging Efficacy in Muscle-Invasive Bladder Cancer
https://www.onclive.com/view/neoadjuvant-atezolizumab-chemo-shows-encouraging-efficacy-in-muscle-invasive-bladder-cancer

Mar 23rd, 2022 - The addition of atezolizumab (Tecentriq) to neoadjuvant gemcitabine and cisplatin (GC) generated a high rate of non–muscle-invasive downstaging following radical cystectomy, which correlated with improved relapse-free survival (RFS) and overall su...

Overuse of Surveillance in Bladder Cancer, Despite Guidelines
https://www.medscape.com/viewarticle/970698

Mar 22nd, 2022 - Clinicians are not following guidelines that recommend a de-escalation in surveillance for patients with low-risk non–muscle-invasive bladder cancer (NMIBC), a new study concludes.   These cancers are associated with low rates of recurrence, progr...

Neoadjuvant Enfortumab Vedotin Demonstrates Encouraging Activity in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
https://www.onclive.com/view/neoadjuvant-enfortumab-vedotin-demonstrates-encouraging-activity-in-cisplatin-ineligible-muscle-invasive-bladder-cancer

Mar 18th, 2022 - Enfortumab vedotin (Padcev) produced promising antitumor activity when used as neoadjuvant treatment in patients with muscle invasive bladder cancer (MIBC) who were not eligible for cisplatin, according to preliminary findings from cohort H of the...

see more →

Patient Education  20 results see all →